Overview

Trial Assessing Zactima Against Placebo in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy

Status:
Terminated

Trial end date:
2010-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether treatment with Zactima for up to 18 months will prolong the off-treatment interval in patients who are undergoing intermittent androgen deprivation therapy.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca
Genzyme, a Sanofi Company

Collaborator:

Canadian Urology Research Consortium

Treatments:

Androgens